Taiwan Defies U.S., Maintains Global Hepatitis B Vaccination for Newborns
Taiwan will continue its longstanding policy of universal hepatitis B vaccinations for all newborns, diverging from a recent controversial decision by U.S. health officials. Teh decision, announced Saturday by the Taiwan Centers for Disease Control (CDC), is rooted in the country’s unique epidemiological context, where mother-to-child transmission accounts for over half of all hepatitis B infections.
The Taiwan CDC’s stance follows consultations with experts from the Advisory committee on Immunization Practices (ACIP), who unanimously recommended maintaining the vaccination policy established in July 1986. According to CDC spokesperson Lin Ming-cheng (林明誠),the continued policy is crucial for further reducing the prevalence of hepatitis B throughout the population.
Under Taiwan’s current protocol, newborns recieve three doses of the hepatitis B vaccine (HBV) – at birth, one month, and six months – to prevent infections that can lead to serious complications like cirrhosis and liver cancer if left untreated. This comprehensive approach has demonstrably lowered infection rates. The country’s high infant vaccination rate has resulted in a dramatic reduction of the hepatitis B carrier rate among children under six to 0.8 percent, a notable drop from 10.5 percent before 1986. Last year alone,vaccination rates for the three doses reached 93.1 percent, 98.9 percent, and 97.9 percent, respectively.
The rationale behind Taiwan’s commitment to universal vaccination stems from the high rate of mother-to-child transmission. Officials emphasize that delaying vaccination even by a short period could compromise its effectiveness in preventing this primary route of infection, especially among individuals born before July 1986, who continue to exhibit higher infection rates.
In contrast, the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices voted Friday to end universal recommendations for hepatitis B vaccinations, opting instead for a case-by-case approach. The U.S.CDC’s decision was reportedly influenced by a study suggesting the universal birth dose had a limited impact on declining acute hepatitis B cases, compared to improvements in blood screening, dialysis practices, and needle exchange programs. The agency also noted that only 0.5 percent of pregnant women in the U.S. test positive for hepatitis B.
However, the U.S. decision has drawn sharp criticism from public health professionals. One public health expert, quoted by the New York Times, stated that the decision marked “a defining moment for our country… We can no longer trust federal health authorities when it comes to vaccines.” Critics within the CDC committee itself have asserted that there is no evidence of vaccine safety concerns and substantial evidence of its effectiveness. A 2023 study published in Public Health Reports, the official journal of the Office of the U.S. Surgeon General, found that infant immunization was “directly linked to a 99 percent decline in acute hepatitis B cases in children, adolescents and young adults between 1990 and 2019.”
In Taiwan, medical experts have voiced strong support for the CDC’s decision. huang Chien-hsien (黃建賢), a physician at the Shin Kong Wu Ho-Su Memorial Hospital, explained that the U.S. may have adjusted its policy due to lower hepatitis B prevalence and cost-effectiveness considerations, but the situation in Taiwan is fundamentally different. Lee ping-ing (李秉穎), a physician and convener of Taiwan’s ACIP, further emphasized that newborns are vulnerable to infection during birth through contact with maternal bodily fluids, and delaying vaccination by even two months woudl negate its protective effect against mother-to-child transmission. Despite a slightly weaker immune response in newborns, studies demonstrate the vaccine still provides over 90 percent protection, validating the policy’s efficacy.
The contrasting approaches highlight the importance of tailoring public health strategies to specific national contexts and prioritizing preventative measures where the risk of transmission remains significant.
